CSPH.F Aperçu des actions CStone Pharmaceuticals, une société biopharmaceutique, recherche, développe et commercialise des médicaments d'immuno-oncologie et de précision pour répondre aux besoins médicaux non satisfaits des patients atteints de cancer en Chine et dans le monde. Plus de détails
Récompenses Analyse des risques Voir tous les contrôles de risques Saisissez vos pensées, vos liens et l'histoire de votre entreprise
CStone Pharmaceuticals Concurrents Historique des prix et performances
Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 CStone Pharmaceuticals Historique des cours de bourse Prix actuel de l'action HK$0.23 Plus haut sur 52 semaines HK$0.26 Plus bas sur 52 semaines HK$0.11 Bêta 0.20 Variation sur 1 mois 0% Variation sur 3 mois n/a Variation sur 1 an n/a Variation sur 3 ans -71.81% Variation sur 5 ans n/a Évolution depuis l'introduction en bourse -79.50%
Nouvelles et mises à jour récentes
CStone Pharmaceuticals Appoints Yip Betty Ho as Independent Non-Executive Director Dec 30
CStone Pharmaceuticals Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody Dec 23
CStone Pharmaceuticals Announces First Patient Enrollment in the Global Multicenter Phase IB Clinical Trial of CS5001 Dec 19
CStone Pharmaceuticals Presents Latest Clinical Data on CS5001 for Advanced Lymphoma Dec 09
CStone Pharmaceuticals Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK Oct 31
CStone Pharmaceuticals to Report First Half, 2024 Results on Aug 23, 2024 Aug 12 Voir plus de mises à jour
CStone Pharmaceuticals Appoints Yip Betty Ho as Independent Non-Executive Director Dec 30
CStone Pharmaceuticals Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody Dec 23
CStone Pharmaceuticals Announces First Patient Enrollment in the Global Multicenter Phase IB Clinical Trial of CS5001 Dec 19
CStone Pharmaceuticals Presents Latest Clinical Data on CS5001 for Advanced Lymphoma Dec 09
CStone Pharmaceuticals Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK Oct 31
CStone Pharmaceuticals to Report First Half, 2024 Results on Aug 23, 2024 Aug 12
CStone Pharmaceuticals Announces European Commission Approval of Sugemalimab (Cejemly) as First-Line Treatment for Non-Small Cell Lung Cancer Jul 26
CStone Pharmaceuticals Announces Change of Joint Company Secretary Jun 19
CStone. Pharmaceuticals Announces Presentation of Latest First-In-Human Data for CS5001 (RoR1 ADC) at ASCO 2024 Jun 05
CStone Pharmaceuticals, Annual General Meeting, Jun 18, 2024 May 26
CStone Pharmaceuticals Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website May 24
CStone Announces the Availability of RET Inhibitor GAVRETO® (palsetinib) Manufacturing Localization Application by Center for Drug Evalence of China NMPA Apr 09
CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer Mar 15 CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma Dec 08
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma Oct 31
CStone Pharmaceuticals Announces Results from A Pivotal Phase III Clinical Trial (GEMSTONE-303), Evaluating Sugemalimab in First-Line GASTRIC or Gastesophageal Junction Adenocarcinoma Oct 25
CStone Pharmaceuticals Announces Receipt of GCP Inspection Notification from the European Medicines Agency Regarding the Marketing Authorization Application Jul 12
CStone Pharmaceuticals Presents Results from Phase 3 Study of Sugemalimab in First-Line Esophageal Squamous Cell Carcinoma at ESMO GI 2023 Jul 01
CStone Pharmaceuticals Announces GAVRETO SNDA Approval by China NMPA for First-Line Treatment of Patients with Locally Advanced or Metastatic Ret Fusion-Positive Non-Small Cell Lung Cancer Jun 27
CStone Pharmaceuticals Announces New Data on AYVAKIT (Avapritinib) in Patients with Advanced Gastrointestinal Stromal Tumor at ASCO 2023 Jun 07 CStone Pharmaceuticals has completed a Follow-on Equity Offering in the amount of HKD 392.8784 million. Feb 17
CStone Pharmaceuticals Provides Earning Guidance for the Year Ended December 31, 2022 Feb 04
Cstone Pharmaceuticals Announces Management Changes Jan 19
CStone Pharmaceuticals Announces the NDA Approval of GAVRETO (Pralsetinib) for the Treatment of Advanced Ret Fusion-Positive Non-Small Cell Lung Cancer and Ret-Altered Thyroid Cancer in Taiwan, China Jan 18 CStone Pharmaceuticals Announces Registrational Clinical Trial of Sugemalimab as First-Line Treatment in Patients with Esophageal Squamous Cell Carcinoma Met Primary Endpoints Jan 03
CStone Pharmaceuticals Announces Results from the Navigator China Bridging Study of AYVAKIT(avapritinib) Published in the Oncologist Dec 29
Cstone Pharmaceuticals Presents Updated Data for Gavreto (Pralsetinib) in Chinese Patients with Ret-Fusion Positive Non-Small Cell Lung Cancer at Esmo Asia Congress 2022 Dec 07
National Medical Products Administration of China Accepts and Grants Priority Review to the Supplemental New Drug Application (sNDA) for sugemalimab of CStone Pharmaceuticals Sep 14
CStone Pharmaceuticals Announces Acceptance of Priority Review to the Supplemental New Drug Application for Sugemalimab Sep 13
CStone Pharmaceuticals to Report First Half, 2022 Results on Aug 25, 2022 Aug 16
CStone Pharmaceuticals Presents Updated Results of Registrational Study of Sugemalimab in Patients with Stage III NSCLC at WCLC 2022 Aug 08
CStone Pharmaceuticals Announces Executive Changes Jul 29
Hong Kong, China Approve GAVRETO of CStone Pharmaceuticals Jul 16
CStone Announces the NDA Approval of GAVRETO® (pralsetinib) for the Treatment of RET Fusion-Positive treatment-naïve (first-line) and pretreated Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China Jul 15
CStone Pharmaceuticals, Annual General Meeting, Jun 30, 2022 Jun 08
CStone Pharmaceuticals Presents Pre-Specified Overall Survival Data of Sugemalimab for First-Line Treatment of Stage Iv Non-Small Cell Lung Cancer At Asco 2022 Jun 07 CStone Pharmaceuticals Presents Updated Results of Anti-PD-1 Antibody Nofazinlimab in Combination with Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma at ASCO 2022
CStone Pharmaceuticals Presents Clinical Results of Sugemalimab in Patients with Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma Via an Oral Abstract Session At ASCO 2022 Jun 04
CStone Pharmaceuticals Announces Final PFS Analysis of Registrational Study of Sugemalimab in Patients with Stage III NSCLC May 17
CStone Pharmaceuticals Announces Publication of Results from the Phase 3 Agile Trial of Tibsovo Apr 22
CStone Pharmaceuticals Announces Presentation of Preclinical Data on A Multi-Specific Antibody-Based Therapeutic Candidate CS2006/NM21-1480 At the American Association for Cancer Research (AACR) Annual Meeting 2022 Apr 13
CStone Pharmaceuticals Announces First Patient Enrollment in the U.S. in the Phase 1 Clinical Trial of Cs5001, A Potential Global Best-In-Class Ror1-Targeting ADC Mar 31
CStone Pharmaceuticals to Report Fiscal Year 2021 Results on Mar 24, 2022 Mar 23
CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) and RET-Altered Thyroid Cancers in Taiwan, China Feb 17
CStone Pharmaceuticals Announced New Drug Approval of China's First Idh1 Inhibitor Tibsovo® (Ivosidenib Tablets) as A New Precision Therapy for Patients with Acute Myeloid Leukemia Feb 09 EQRx, Inc. and CStone Pharmaceuticals Announce Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer
CStone Pharmaceuticals Announces Two Key Phase 3 Registrational Clinical Trials of Sugemalimab Completed Patient Enrollment Jan 18 Cstone Pharmaceuticals Announces the Registrational Clinical Study Results of Sugemalimab in Stage IV Non-Small Cell Lung Cancer Published in the Lancet Oncology
CStone Announces Phase 2 GEMSTONE-201 Trial Met Primary Endpoint of Objective Response Rate (ORR) in Patients with Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL) Jan 13
CStone Announces IND Approval for the Pivotal Study in China of Lorlatinib for the Treatment of ROS1-Positive Advanced Non-Small Cell Lung Cancer Jan 05
CStone Pharmaceuticals Announces the IND Approval of CS5001, a Potential Global Best-In-Class ROR1-Targeting ADC by the U.S. Food and Drug Administration Jan 04
CStone Announces New Drug Approval of Precision Therapy AYVAKIT® (Avapritinib) in Hong Kong, China for the Treatment of PDGFRA D842V Mutant Gastrointestinal Stromal Tumors (GIST) Dec 28
CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy Dec 23
CStone Pharmaceuticals Announces New Drug Approval of Cejemly (Sugemalimab) in China to Potentially Reshape the Landscape of Immuno-Oncology Therapy in Lung Cancer Dec 22
Cstone Presents Preliminary Results from Phase Ib Study of the Anti-Ctla-4 Monoclonal Antibody (Mab) Cs1002 in Combination with the Anti-Pd-1 Mab Cs1003 in Patients with Advanced Solid Tumors at ESMO 2021 Sep 21
EQRx and its Partner CStone Pharmaceuticals Announce Presentation of Phase 3 Data Demonstrating Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021 Sep 20
CStone Pharmaceuticals Will Present Registrational Clinical Study Data of Sugemalimab in Patients with Stage III Non-Small Cell Lung Cancer in an Oral Presentation At ESMO Congress 2021 Sep 19 CStone Pharmaceuticals Receives China NMPA IND Approval for CS2006/NM21-1480, a PD-L1/4-1BB/HSA Multi-Specific Antibody, Marking Further Expansion of Its Pipeline 2.0
CStone Pharmaceuticals Presents Registrational Bridging Study Data for Gavreto (Pralsetinib) Highlighting Efficacy and Safety in Chinese Patients with Advanced Ret Fusion-Positive Non-Small Cell Lung Cancer at Iaslc Wclc 2021 Sep 09
National Medical Products Administration of China Accepts New Drug Application for Sugemalimab of CStone Pharmaceuticals as Consolidation Therapy Sep 02
CStone's Partner Servier Announces Positive Topline Data from the Global Phase III Study of Tibsovo (Ivosidenib Tablets) in Combination with Azacitidine Aug 06
Cstone Pharmaceuticals Announces China Registrational Study CS3010-101 of Tibsovo Aug 04
CStone Pharmaceuticals Announces Positive Registrational Study of GAVRETO® (pralsetinib) in Chinese Patients with RET-mutant medullary thyroid cancer Jun 30
CStone Pharmaceuticals Announces GAVRETO (Pralsetinib) Issued Across Guangdong Province People's Hospital and Around 100 Other Hospitals Across China Jun 22
EQRx, along with its partner CStone Pharmaceuticals Announces Phase 3 Study of the Anti-PD-L1 Antibody Sugemalimab in Stage III Non-Small Cell Lung Cancer May 29
CStone Pharmaceuticals Announces the First-In-Class Registrational Clinical Trial of Sugemalimab Met Its Primary Endpoint in Stage Iii Nsclc and Plans to Submit A New Drug Application May 28
CStone Announces Acceptance of New Drug Application in Hong Kong for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumor May 12
CStone Announces NMPA Acceptance of New Drug Application of Selective Inhibitor GAVRETO(R) (Pralsetinib) with Priority Review Designation for the Treatment of Advanced or Metastatic RET-Altered Thyroid Cancer Patients Apr 27
CStone Pharmaceuticals to Report Fiscal Year 2020 Results on Mar 25, 2021 Mar 16
CStone Announces Another Breakthrough Therapy Designation Granted for Sugemalimab by China National Medical Products Administration Feb 10
CStone Pharmaceuticals Reports Efficacy and Safety Data from the ARROW Trial of Pralsetinib in Chinese Patients with Advanced Ret Fusion-Positive Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy At IASLC WCLC 2020 Jan 29
CStone Pharmaceuticals Announces Company Secretary Changes, Effective 25 January 2021 Jan 26
Cstone Pharmaceuticals Announces the Results of GEMSTONE-302 Nov 24
CStone Pharmaceuticals Announces China's NMPA has Accepted its New Drug Application for anti-PD-L1 Monoclonal Antibody Sugemalimab in First-Line Advanced NSCLC Nov 12
CStone Pharmaceuticals Announces an Agreement to Out-License Ex-Greater China Rights for Two Key Late-Stage Immuno-Oncology Assets Oct 29
CStone Pharmaceuticals announced that it expects to receive $45 million in funding from Suzhou Industrial Park District Yuanhe Yuandian Venture Capital Management Co., Ltd. Oct 06
CStone Pharmaceuticals announced that it has received $45 million in funding from Suzhou Industrial Park District Yuanhe Yuandian Venture Capital Management Co., Ltd. Oct 05
CStone Pharmaceuticals announced that it expects to receive HKD 1.549968096 billion in funding from Pfizer Corporation Hong Kong Limited Oct 03
CStone Pharmaceuticals, Pfizer Investment Co. Ltd. and Pfizer Corporation Hong Kong Limited Announce Formation of Strategic Collaboration Sep 30 Genetron Holdings Limited and Cstone Pharmaceuticals Announce Launch of Clinical Trial in China for Companion Diagnostic Test in Development for Avapritinib Rendement pour les actionnaires CSPH.F US Biotechs US Marché 7D 0% 3.6% 3.8% 1Y n/a -6.1% 24.4%
Voir le rapport complet des actionnaires
Rendement vs Industrie: Données insuffisantes pour déterminer la performance de CSPH.F par rapport au secteur US Biotechs.
Rendement vs marché: Données insuffisantes pour déterminer la performance de CSPH.F par rapport au marché US.
Volatilité des prix Is CSPH.F's price volatile compared to industry and market? CSPH.F volatility CSPH.F Average Weekly Movement n/a Biotechs Industry Average Movement 11.3% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.9% 10% least volatile stocks in US Market 3.2%
Cours de l'action stable: Le cours de l'action de CSPH.F a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de CSPH.F au cours de l'année écoulée.
À propos de l'entreprise CStone Pharmaceuticals, une société biopharmaceutique, recherche, développe et commercialise des médicaments d'immuno-oncologie et de précision pour répondre aux besoins médicaux non satisfaits des patients atteints de cancer en Chine et dans le monde. Elle propose le sugemalimab, un anticorps monoclonal contre le ligand 1 de la mort programmée (PD) ; GAVRETO, un inhibiteur de RET pour le traitement des patients atteints de cancers médullaires avancés ou métastatiques mutés RET et de cancers de la thyroïde positifs à la fusion RET ; et l'avapritinib, un inhibiteur de KIT/PDGFRA pour traiter les adultes atteints de tumeurs stromales gastro-intestinales non résécables ou métastatiques présentant une mutation de l'exon 18 de PDGFRA. Le portefeuille de produits de la société comprend le Nofazinlimab, un anticorps PD-1 pour le traitement des patients atteints de carcinome hépatocellulaire, et l'Ivosidenib, un inhibiteur de l'isocitrate déshydrogénase 1 (IDH1) pour traiter les adultes atteints de leucémie myéloïde aiguë récidivante ou réfractaire avec une mutation IDH1.
Afficher plus CStone Pharmaceuticals Résumé des fondamentaux Comment les bénéfices et les revenus de CStone Pharmaceuticals se comparent-ils à sa capitalisation boursière ? CSPH.F statistiques fondamentales Capitalisation boursière US$390.03m Bénéfices(TTM) -US$19.55m Recettes(TTM ) US$62.72m
Bénéfices et recettes Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM) CSPH.F compte de résultat (TTM ) Recettes CN¥456.53m Coût des recettes CN¥133.65m Marge brute CN¥322.89m Autres dépenses CN¥465.20m Les revenus -CN¥142.31m
Derniers bénéfices déclarés
Jun 30, 2024
Prochaine date de publication des résultats
s/o
Résultat par action (EPS) -0.11 Marge brute 70.73% Marge bénéficiaire nette -31.17% Ratio dettes/capitaux propres 65.5%
Quelles ont été les performances à long terme de CSPH.F?
Voir les performances historiques et les comparaisons
Analyse de l'entreprise et données financières Données Dernière mise à jour (heure UTC) Analyse de l'entreprise 2025/01/22 02:25 Cours de l'action en fin de journée 2024/11/22 00:00 Les revenus 2024/06/30 Revenus annuels 2023/12/31
Sources de données Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC . Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
Paquet Données Cadre temporel Exemple de source américaine * Finances de l'entreprise 10 ans Compte de résultat Tableau des flux de trésorerie Bilan Estimations consensuelles des analystes +3 ans Prévisions financières Objectifs de prix des analystes Prix du marché 30 ans Cours des actions Dividendes, scissions et actions Propriété 10 ans Actionnaires principaux Délits d'initiés Gestion 10 ans L'équipe dirigeante Conseil d'administration Principaux développements 10 ans
* exemple pour les titres américains, pour les titres non-américains des formulaires et sources réglementaires équivalents sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). Pour en savoir plus , cliquez ici .
Modèle d'analyse et flocon de neige Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github . Nous avons également des guides sur la façon d'utiliser nos rapports et des tutoriels sur Youtube .
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur .
Sources des analystes CStone Pharmaceuticals est couverte par 3 analystes. 1 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
Analyste Institution Ziyi Chen Goldman Sachs Ling Wang J.P. Morgan Sean Wu Morgan Stanley
Afficher 0 plus d'analystes 
